Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ASLN
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
zacks.com
10 hours ago
zacks.com
13 hours ago
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
NASDAQ
Unprofitable
Unprofitable
-0.10Ā ( -14.27%)
Relative Strenght
1
Volume Buzz
651%
Earning Acce
No
Dist 52w H.
96%Quote Panel
Key Metrics
Relative Strength
ASLN
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Earnings Growth
YoY
Current
Estimates
Q2.22
N/A
-7.60
vsĀ -3.20
Q3.22
N/A
-6.40
vsĀ -4.80
Q4.22
N/A
-8.32
vsĀ -6.40
Q1.23
N/A
-10.32
vsĀ -7.60
Q2.23
N/A
-0.88
vsĀ -7.60
Q3.23
N/A
-4.48
vsĀ -6.40
Q4.23
N/A
-0.78
vsĀ -8.32
Q1.24
N/A
-6.24
vsĀ -10.32
Q2.24
N/A
-0.16
vsĀ -0.88
Q3.24
N/A
-0.16
vsĀ -4.48
Sales Growth
YoY
Current
Estimates
Q4.21
NA
NAĀ vsĀ NA
Q1.22
NA
NAĀ vsĀ NA
Q2.22
NA
NAĀ vsĀ NA
Q3.22
NA
NAĀ vsĀ NA
Q4.22
NA
NAĀ vsĀ NA
Q1.23
NA
NAĀ vsĀ NA
Q2.23
NA
12MĀ vsĀ NA
Q3.23
NA
NAĀ vsĀ NA
Q4.23
NA
NAĀ vsĀ NA
Q1.24
NA
NAĀ vsĀ NA
Return on Equity
QoQ
Q4.21
-16%
-0.16
vsĀ -0.13
Q1.22
-29%
-0.29
vsĀ -0.16
Q2.22
-39%
-0.39
vsĀ -0.29
Q3.22
-50%
-0.50
vsĀ -0.39
Q4.22
-173%
-1.73
vsĀ -0.50
Q1.23
-193%
-1.93
vsĀ -1.73
Q2.23
-30%
-0.30
vsĀ -1.93
Q3.23
+1101%
11.01
vsĀ -0.30
Q4.23
+102%
1.02
vsĀ 11.01
Q1.24
+55%
0.55
vsĀ 1.02
Institutionnal Ownership
QoQ
Q4.22
25
25
vsĀ 27
-7%
Q1.23
16
16
vsĀ 25
-36%
Q2.23
23
23
vsĀ 16
44%
Q3.23
21
21
vsĀ 23
-9%
Q4.23
21
21
vsĀ 21
NA
Q1.24
22
22
vsĀ 21
5%
Q2.24
18
18
vsĀ 22
-18%
Q3.24
1
1
vsĀ 18
-94%
Q4.24
1
1
vsĀ 1
NA
Q1.25
1
1
vsĀ 1
NA
Forecast
2025-Revenue
-42%2025-EPS
115%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available